Dados B3 › MRVE3 × RADL3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | MRVE3 | RADL3 | year |
|---|---|---|---|
| ROE | -17.7% | 18.9% | 2025 |
| ROIC | 0.8%! | 24.8% | 2025 |
| ROA | -3.6% | 5.5% | 2025 |
| Gross margin | 29.3% | 29.3% | 2025 |
| EBIT margin | 1.8% | 6.2% | 2025 |
| Net margin | -9.6% | 2.9% | 2025 |
| Net debt/EBITDA | 12.95x | 0.69x | 2025 |
| Current ratio | 2.03x | 1.46x | 2025 |
| Revenue growth (1y) | 21.1% | 13.8% | 2025 |
| Revenue growth (5y CAGR) | 10.4% | 17.1% | 2025 |
| Piotroski F-Score | 6/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | MRVE3 | RADL3 | year |
|---|---|---|---|
| P/E | -4.63x | 32.24x | 2025 |
| P/B | 0.91x | 5.71x | 2025 |
| EV/EBITDA | 20.43x | 9.37x | 2025 |
| FCF yield | 5.0% | 2.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:11 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it